Citicoline
Citicoline is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
65 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glaucoma | D005901 | EFO_0000516 | H40 | 1 | — | 2 | 1 | 9 | 13 |
| Ischemia | D007511 | EFO_0000556 | — | 2 | — | 4 | 1 | 2 | 9 |
| Cerebral infarction | D002544 | — | I63 | — | — | 4 | 1 | 2 | 7 |
| Brain injuries | D001930 | — | S06.9 | — | 2 | 1 | 1 | 1 | 5 |
| Traumatic brain injuries | D000070642 | — | S06 | — | 1 | 1 | 1 | 1 | 4 |
| Optic nerve diseases | D009901 | EFO_1001330 | H47.14 | — | — | — | 2 | 2 | 4 |
| Infarction | D007238 | EFO_0009463 | — | — | — | 1 | 1 | 1 | 3 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 2 | 1 | 3 |
| Ischemic optic neuropathy | D018917 | EFO_1000809 | H47.01 | — | — | — | 2 | 1 | 3 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | — | 2 | — | 3 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | 1 | — | 1 | — | 6 | 8 |
| Ischemic stroke | D000083242 | — | — | 2 | 1 | 4 | — | 1 | 7 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 1 | 5 | — | 1 | 7 |
| Hypoxia | D000860 | HP_0012418 | R09.02 | 1 | — | 2 | — | — | 3 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | 1 | — | 1 | 2 |
| Brain diseases | D001927 | HP_0001298 | G93.40 | 1 | — | 1 | — | — | 2 |
| Brain ischemia | D002545 | EFO_0003883 | I67.82 | 1 | — | 1 | — | — | 2 |
| Brain hypoxia-ischemia | D020925 | EFO_1000846 | P91.6 | 1 | — | 1 | — | — | 2 |
| Mania | D000087122 | — | — | — | — | 1 | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 2 | — | — | — | 2 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 1 | — | — | 1 | 2 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 1 | — | — | 1 | 2 |
| Ataxia | D001259 | — | R27.0 | — | 1 | — | — | — | 1 |
| Tremor | D014202 | HP_0001337 | R25.1 | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Cerebellar ataxia | D002524 | HP_0001251 | — | — | 1 | — | — | — | 1 |
| Cognition disorders | D003072 | — | — | — | 1 | — | — | — | 1 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 1 | — | — | — | 1 |
| Covid-19 | D000086382 | — | — | 1 | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal diseases | D012164 | HP_0000479 | H35.9 | 1 | — | — | — | 1 | 2 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | 1 | — | — | — | 1 | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | — | — | 4 | 4 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 2 | 2 |
| Corneal diseases | D003316 | — | H18.9 | — | — | — | — | 1 | 1 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | — | — | — | — | 1 | 1 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 1 | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | — | 1 | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | — | 1 | 1 |
| Visual fields | D014794 | — | — | — | — | — | — | 1 | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 1 | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Citicoline |
| INN | citicoline |
| Description | CDP-choline is a member of the class of phosphocholines that is the chloine ester of CDP. It is an intermediate obtained in the biosynthetic pathway of structural phospholipids in cell membranes. It has a role as a human metabolite, a psychotropic drug, a neuroprotective agent, a Saccharomyces cerevisiae metabolite and a mouse metabolite. It is a member of phosphocholines and a member of nucleotide-(amino alcohol)s. It is functionally related to a CDP. It is a conjugate base of a CDP-choline(1+). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[N+](C)(C)CCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 987-78-0 |
| RxCUI | 997602 |
| ChEMBL ID | CHEMBL1618340 |
| ChEBI ID | 49086 |
| PubChem CID | 13804 |
| DrugBank | DB12153 |
| UNII ID | 536BQ2JVC7 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,883 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
140 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use